ArticleOncotarget2015
CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Review
- Deciphering the role of cathepsins in digestive system cancers: a Mendelian randomization study.Discover oncology · 2025Article
- CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms.Cancer genomics & proteomics · 2025Article
- Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.Nature communications · 2022Article
- Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.FEBS open bio · 2022Review
- Helicobacter pylori and gastric cancer: a lysosomal protease perspective.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Review
- Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.Nature communications · 2021Article
- Role of lysosomes in physiological activities, diseases, and therapy.Journal of hematology & oncology · 2021Review
- Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.Breast cancer research : BCR · 2020Article
- Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery.Cells · 2020Review
- Cathepsin S as a target in gastric cancer.Molecular and clinical oncology · 2020Article
- Lysosomal peptidases in innate immune cells: implications for cancer immunity.Cancer immunology, immunotherapy : CII · 2020Review
- Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.Arthritis research & therapy · 2019Article
- Cysteine Cathepsins in Tumor-Associated Immune Cells.Frontiers in immunology · 2019Review
- Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles.The EMBO journal · 2017Article
- The biological function and significance of CD74 in immune diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- CD74 and intratumoral immune response in breast cancer.Oncotarget · 2017Article
- Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.The international journal of biochemistry & cell biology · 2016Article
- Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Cathepsins S (CatS) has been implicated in numerous tumourigenic processes and here we document for the first time its involvement in CCL2 regulation within the tumour microenvironment. Analysis of syngeneic tumours highlighted reduced infiltrating macrophages in CatS depleted tumours. Interrogation of tumours and serum revealed genetic ablation of CatS leads to the depletion of several pro-inflammatory chemokines, most notably, CCL2. This observation was validated in vitro, where shRNA depletion of CatS resulted in reduced CCL2 expression. This regulation is transcriptionally mediated, as evident from RT-PCR analysis and CCL2 promoter studies. We revealed that CatS regulation of CCL2 is modulated through CD74 (also known as the invariant chain), a known substrate of CatS and a mediator of NFkB activity. Furthermore, CatS and CCL2 show a strong clinical correlation in brain, breast and colon tumours. In summary, these results highlight a novel mechanism by which CatS controls CCL2, which may present a useful pharmacodynamic marker for CatS inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.